ISB 2001 (ABBV-2001) is an investigational first- and only-in-class CD38 × BCMA × CD3 trispecific T-cell engager.
It is engineered using IGI's BEAT® Multispecific Platform and coordinates dual-antigen tumor recognition with immune engagement through T cells within a single molecular architecture.
It is in development for the treatment of relapsed/refractory multiple myeloma (RRMM).
Clinical Data Update
Updated clinical data from the Phase 1 TRIgnite-1 study of ISB 2001 will be presented as an oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting.
The data include longer follow-up from the dose-escalation phase and early results from dose-expansion cohorts in patients with heavily pretreated multiple myeloma.
Presentation details: Date and Time: Saturday, December 12, 2026, 4–4:15pm CST; Room: La Nouvelle C at the Ernest N. Morial Convention Center, New Orleans; Session: 654. Multiple Myeloma: Pharmacologic Therapies: The March of Immunotherapy.
Presenter: Binod Dhakal, M.D., Medical College of Wisconsin (MCW).
Strategic Context and Management Commentary
IGI and AbbVie formed an exclusive global licensing agreement for ISB 2001 in July 2025.
ISB 2001 is being evaluated in the Phase 1 TRIgnite-1 study and a Phase 1/2 combination study for multiple myeloma.
Lida Pacaud, M.D., President and Chief Executive Officer of IGI, commented: "With longer follow-up from dose escalation and initial results from dose expansion, ISB 2001 (ABBV-2001) continues to demonstrate robust efficacy and tolerability in heavily pretreated patients with relapsed/refractory multiple myeloma. These results represent an important milestone in the development of this first and only trispecific T-cell engager targeting CD38 x BCMA x CD3. Together with our partner, AbbVie, we remain focused on advancing ISB 2001 (ABBV-2001) as a potential new treatment option for patients with relapsed/refractory multiple myeloma (RRMM)."
Additional Information
IGI is a global clinical-stage biotechnology company developing Multispecific™ therapeutics in oncology, headquartered in New York, NY.
The press release was submitted to BSE Limited and National Stock Exchange of India Limited by Glenmark Pharmaceuticals Limited under reference number 63/26-27.
